Verona Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide …

Two additional formulations of ensifentrine have been evaluated in Phase 2 studies for the treatment of COPD: dry powder inhaler (“DPI”) and …

Share on Facebook

Tweet

Follow us

Save